Abstract
Recently, glucagon-like peptide 1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) have received much attention regarding possible roles in aetiology and treatment of type 2 diabetes. However, peptides co-secreted from the same enteroendocrine cells are less well studied. The present investigation was designed to characterise the in vitro and in vivo effects of xenin, a peptide co-secreted with GIP from intestinal K-cells. We examined the enzymatic stability, insulin-releasing activity and associated cAMP production capability of xenin in vitro. In addition, the effects of xenin on satiety, glucose homoeostasis and insulin secretion were examined in vivo.
Original language | English |
---|---|
Pages (from-to) | 87-93 |
Number of pages | 7 |
Journal | Journal of Endocrinology |
Volume | 207 |
Issue number | 1 |
DOIs | |
Publication status | Published - Oct 2010 |
Keywords
- xenin peptide
- insulin secretion
- type 2 diabetes
- glucose homoeostasis